Accessibility Menu
Adial Pharmaceuticals logo

Adial Pharmaceuticals(NASDAQ) ADIL

Market Cap$10.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-53%
1 Month+65%
$4.72
-1.67%
-0.08Today
Adial Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 4.802026-08-06
Adial Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+45.9%USD 3.292026-07-30
1 month+64.95%USD 2.912026-07-07
3 month+235.66%USD 1.432026-05-08
Year to date-12.73%USD 5.502025-12-31
1 year-53.49%USD 10.322025-08-06
3 year-96.91%USD 155.502023-08-07
5 year-99.72%USD 1,718.752021-08-06
Since inception-99.81%USD 2,531.252018-07-27

Adial Pharmaceuticals Financials at a Glance

Market Cap

$10.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.77M

EPS (TTM)

-$9.90

P/E Ratio

-0.48

Dividend

$0.00

Beta (Volatility)

0.77 (Low)

Price

$4.72

Volume

12,413.748

Open

$4.80

Previous Close

$4.80

Daily Range

$4.56 - $4.87

52-Week Range

$1.31 - $10.75

Estimated Earnings Date

Aug 12, 2026

ADIL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adial Pharmaceuticals

Adial develops medicines for people struggling with addiction, especially alcohol use disorder. Its main drug, AD04, aims to help those with specific genetic traits. The company also explores treatments for pain and other disorders.

What’s in the Medicine Cabinet?

  • AD04 (Lead Drug): A medicine in late-stage testing for alcohol use disorder, targeting patients with certain genes. (0% of revenue; no sales yet)
  • Companion Diagnostic: A genetic test to identify patients most likely to benefit from AD04. (0% of revenue)
  • Non-Opioid Pain Candidates: Early-stage drugs for pain relief without using opioids, previously developed through a subsidiary. (0% of revenue)
  • Equity Stake in Adovate: Holds a share in a company developing related drug assets after selling its former subsidiary’s assets. (0% of revenue)

Growth and Expansion: The Road So Far

  • Sold subsidiary Purnovate’s assets to Adovate in 2023, retaining an equity stake.
  • Completed a Phase 1 study of AD04 in 2024 to support further clinical trials.
  • Signed an approximately $2.3 million contract in 2025 for AD04 manufacturing and validation for Phase III trials.
  • Raised approximately $5.3 million in new capital through warrant exercises and equity offerings in May and June 2025.
  • Secured a new US patent in April 2025 for AD04’s use in genetically defined patient groups.

What Makes Adial Stand Out in the Crowd?

Adial uses a precision medicine approach, matching treatments to patients’ genetic profiles. Its focus is on addiction disorders with few current options. The company holds exclusive rights to patents for its main drug in key markets.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Operating loss was $1.88 million in Q2 2025, down 17.9% from Q2 2024.
  • Cash and equivalents were $5.91 million as of June 30, 2025, up 57.6% from December 2024.
  • R&D expenses were $0.73 million in Q2 2025, down 28% year-over-year.
  • Accumulated deficit reached $86.2 million as of June 30, 2025.

Bottom Line

Adial remains focused on developing targeted treatments for addiction, with no commercial sales to date. The company’s future depends on clinical progress and securing additional funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6

CEO

Cary J. Claiborne, MBA

Website

www.adial.com

Headquarters

Glen Allen, VA 23060, US

ADIL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-162.83%

Return on Capital

-147.82%

Return on Assets

-148.66%

Earnings Yield

-2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.19M

Volume

12.41K

Avg. Volume

455.53K

Financials (TTM)

Gross Profit

-$141.00

Operating Income

-$7.53M

EBITDA

-$7.77M

Operating Cash Flow

-$6.52M

Capital Expenditure

-$1.00

Free Cash Flow

-$6.52M

Cash & ST Invst.

$4.58M

Total Debt

$0.00

Adial Pharmaceuticals Performance Analysis

Adial Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Adial Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Adial Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -7,945.181116.6%
20232023-12-31USD -135.96-98.3%
20242024-12-31USD -68.01-50.0%
20252025-12-31USD -11.93-82.5%
Adial Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3047.1%
Q32025-09-3055.6%
Q42025-12-3110.0%
Q12026-03-3117.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$141.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$10.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.75M

N/A

Employees

6

N/A

Net Income

-$2.02M

+9.3%

EBITDA

-$2.02M

+9.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.58M

+93.8%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.49%

N/A

Return on Invested Capital

-2.03%

N/A

Free Cash Flow

-$1.61M

-1.7%

Operating Cash Flow

-$1.61M

-1.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCDABioCardia, Inc.
$0.93-1.99%
KPRXKiora Pharmaceuticals, Inc.
$2.59+1.17%
BCLIBrainstorm Cell Therapeutics Inc.
$0.80+0.00%
APREAprea Therapeutics, Inc.
$0.64+0.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$125.07+0.09%
TTDThe Trade Desk
$14.16-0.20%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.50+0.02%
INTCIntel
$99.69-0.00%

Questions About ADIL

What is the current price of Adial Pharmaceuticals?

Adial Pharmaceuticals is trading at $4.66 per share.

What is the 52-week range for Adial Pharmaceuticals?

Over the past 52 weeks, Adial Pharmaceuticals has traded between $1.31 and $10.75.

How much debt does Adial Pharmaceuticals have?

As of the most recent reporting period, Adial Pharmaceuticals reported total debt of $0.00.

How much cash does Adial Pharmaceuticals have on hand?

Adial Pharmaceuticals reported $4.58M in cash and cash equivalents in its most recent financial results.

What is Adial Pharmaceuticals’s dividend yield?

Adial Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services